Meeting
2023 ASCO Genitourinary Cancers Symposium
LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors
Louise Kathleen Kostos
Department of Medical Oncology, Peter MacCallum Cancer Centre; and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
Louise Kathleen Kostos , James Patrick Buteau , Grace Kong , Theresa Yeung , Juliana Di Iulio , Michael T Fahey , Heidi Fettke , Luc Furic , Michael S Hofman , Arun Azad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05340374
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS278)
DOI
10.1200/JCO.2023.41.6_suppl.TPS278
Abstract #
TPS278
Poster Bd #
P20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study.
First Author: Ronan Flippot
Poster
2021 Genitourinary Cancers Symposium
Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial).
First Author: Sarennya Pathmanandavel
Poster
2020 Genitourinary Cancers Symposium
Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).
First Author: Louise Emmett
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan